MAP2K7 and non-small cell lung carcinoma: In a phase Ib trial, belvarafenib, another dimer selective RAF inhibitor, in combination with the MEK inhibitor cobimetinib, demonstrated a partial response in two BRAF non-V600-mutant NSCLC patients tested [163].